patent.fyi
Applications  /  US 2026/0355263
United States Patent Application Publication

US 2026/0355263 A1

Published
Nov 12, 2026
Filed
Jul 17, 2026
Earliest date on the face
Dec 20, 2019
Classification
A61K 35/744
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Intestinal enzyme inhibition

What ifWhat if an oral tablet limited post-meal glucose excursions by slowing starch digestion?
Claim language“Pediococcus acidilactici CECT 9967”

The tablet releases an alpha-glucosidase inhibitor taken with a carbohydrate-containing meal. The inhibitor slows the breakdown of starch-derived carbohydrates into glucose at the small-intestinal brush border.

1.1Viscous soluble fiber

What ifWhat if an orally consumed fiber gel slowed the entry of meal-derived glucose into the bloodstream?
Claim language“Pediococcus acidilactici CECT 9967”

A powder containing psyllium husk is dispersed in water and consumed with a meal. The hydrated fiber increases the viscosity of intestinal contents and slows glucose absorption.

1.1Reduced hepatic glucose output

What ifWhat if an oral biguanide lowered blood glucose by reducing glucose production in the liver?
Claim language“Pediococcus acidilactici CECT 9967”

A tablet releases a biguanide that enters the circulation after intestinal absorption. The compound reduces hepatic glucose output, which lowers fasting blood glucose.

1.1Reduced renal glucose reabsorption

What ifWhat if an oral small molecule lowered blood glucose by increasing glucose excretion in urine?
Claim language“Pediococcus acidilactici CECT 9967”

A tablet releases an inhibitor of the sodium-glucose cotransporter in the proximal renal tubule. Inhibition reduces the fraction of filtered glucose returned to the bloodstream and increases urinary glucose excretion.

1.1Prolonged endogenous incretin activity

What ifWhat if an oral enzyme inhibitor prolonged the body's incretin response to meals?
Claim language“Pediococcus acidilactici CECT 9967”

A tablet delivers an inhibitor of dipeptidyl peptidase 4, an enzyme that degrades endogenous incretin hormones. The longer-lived incretin signal increases glucose-dependent insulin secretion and reduces glucagon secretion when blood glucose is elevated.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Individual dosing in a veterinary hospital

A veterinary inpatient unit stores individually packaged oral doses of the live bacterial strain. The caregiver empties one package into a small serving of the animal’s prescribed wet food and offers it in a separate bowl before the main meal. The caregiver records the package identifier, administration time, and whether the animal consumes the entire serving.

Component substitution

Soft veterinary chew with live bacteria

A soft chew replaces the capsule shell and loose powder of an encapsulated oral formulation. A premeasured portion of dried live culture is enclosed in a soft feed matrix after the matrix cools to room temperature. Each chew is sealed individually, and representative units undergo viable plate counts after assembly and at the end of the intended storage period.

Parameter or scale variation

Two smaller portions per day

A study schedule divides a daily total of 1 × 10⁹ viable bacteria into two oral portions of 5 × 10⁸ viable bacteria each. Separate sachets hold the morning and evening portions, which are offered 12 hours apart. A comparison group receives the same daily total in one portion, and both groups follow the same feeding and glucose sampling schedules.

Combination with existing systems

Oral dosing linked to glucose monitoring

A glucose monitor with a subcutaneous sensor records interstitial glucose during a veterinary feeding study. A caregiver records each oral dose and meal time in an electronic log that uses the same clock as the monitor. Analysis software aligns the sensor readings with meal times and calculates the glucose excursion above the premeal reading over the next two hours.

Automated or data-driven variant

Viable counts control sachet fill mass

A powder filling station connects a gravimetric feeder and a checkweigher to a controller that reads a lot-specific viable count in colony-forming units per gram. The controller divides the target colony-forming units per sachet by the measured count per gram to calculate the powder fill mass. The checkweigher diverts sachets outside the programmed mass tolerance, and finished samples undergo a separate viable count to verify the delivered amount.

Specific version of a part

Freeze dried oral capsule

A hard cellulose capsule contains freeze-dried cells of the specified strain blended with a dry carrier. The capsule shell dissolves after swallowing and releases the powder into gastrointestinal fluid.

Oral feed pellet coating

A dry powder containing the specified strain adheres to cooled feed pellets through a thin edible oil coating. The animal consumes the coated pellets, and the cells disperse as the pellets hydrate in the digestive tract.

Single measured daily portion

One premeasured portion provides 100 million viable bacteria per day. A lot-specific viable count per gram determines the powder mass placed in each portion.

Two portions per day

Two oral portions each provide 50 million viable bacteria and are administered about 12 hours apart. Together the portions deliver 100 million viable bacteria per 24-hour period.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2011/0091432 A1
Published
Apr 21, 2011
Filed
Jun 18, 2010
Class
A61K 35/74
Document BUS 9,402,871 B2
Published
Aug 2, 2016
Filed
Mar 18, 2015
Class
A61K 35/744
Claim 1
Document A
Document B
1.1orally administering to said animal an effective amount of Pediococcus acidilactici CECT 9967
Besides the oral dosage form, the pharmaceutical composition containing the isolated Pediococcus acidilactici 05B0111 can also be formulated into a suitable dosage form for topical administration (e.g., percutaneous administration or intranasal administration).
A · US 2011/0091432 A1 · ¶ 38
In another exemplary embodiment, Pediococcus acidilactici P1J e3 alone is administered to animals such as lactating sows and/or to piglets.
B · US 9,402,871 B2 · ¶ 32
1.2wherein the effective amount is 104 to 1012 bacteria per dose, per day, or per 24-hour period.
The eight probiotic treatments were formulated to deliver 1×109 total cfu/pig/day to sows or pigs regardless of whether the total cfu was derived from one organism or a combination of the three selected organisms, with equal amounts (based on CFUs) of each organism included where multiple organisms were used.
B · US 9,402,871 B2 · ¶ 75

An empty cell means only that no passage was reproduced there.

Statements in these documents
However, EPS produced by bacteria are usually unstable, and yield of the same is normally very low.
A · US 2011/0091432 A1 · ¶ 9
Since EPS is in great demand, various factors affecting productivity of EPS of LAB have been investigated so as to develop a new cultivation technology for increasing yield of EPS.
A · US 2011/0091432 A1 · ¶ 9
This has led to great interest in the use of direct-fed microbial (DFM) additives to aid the weaning transition by preventing the disruption of the gastrointestinal ecosystem that paves the way for pathogen invasion, thereby promoting growth and maintaining health in the young pig.
B · US 9,402,871 B2 · ¶ 7
Therefore, bacteria used for DFM products for livestock species are not usually selected to provide bacterial organisms that would be ideally suited for the challenges present in livestock production systems.
B · US 9,402,871 B2 · ¶ 8
Cite aspatent.fyi, US 2026/0355263 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355263/, SHA-256 448f6a1f963a09caefed89c59717f90b305e331a90e9b161db1bd0d69b72666f
First published
Permanent addresshttps://patent.fyi/US20260355263/
Content fingerprint (SHA-256)448f6a1f963a09caefed89c59717f90b305e331a90e9b161db1bd0d69b72666f
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi